


PHARMACEUTICAL 2017

HARROW INC. Rank 213 of 292







PHARMACEUTICAL 2017

HARROW INC. Rank 213 of 292



The relative strengths and weaknesses of HARROW INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HARROW INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 59% points. The greatest weakness of HARROW INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -33%, being 36% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	14,753
Cost of Goods Sold	0
Intangible Assets	5,199
Liabilities, Current	9,905
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	17,516
Other Liabilities	10,910
Other Net Income	-3,205
Other Revenues	19,942
Property and Equipment	7,295
Research and Development	739
Selling, General and Administrative Expense	17,569

Output Variable	Value in 1000 USD
Assets	27,247
Liabilities	20,815
Expenses	35,824
Revenues	19,942
Stockholders Equity	6,432
Net Income	-19,087
Comprehensive Net Income	-19,087
Economic Capital Ratio	-33%

